Author: Benzinga Newsdesk | August 11, 2025 04:24pm
Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.46) by 23.11 percent. This is a 62.86 percent decrease over losses of $(0.35) per share from the same period last year.